Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320804044> ?p ?o ?g. }
- W4320804044 endingPage "574" @default.
- W4320804044 startingPage "565" @default.
- W4320804044 abstract "Neutrophils (polymorphonuclear neutrophils [PMNs]) have been implicated as mediators of reperfusion injury. Heparin, urokinase, and ancrod are agents used routinely to prevent and treat thrombosis, yet their effects on PMN function are unknown. Therefore human PMNs were obtained and incubated for 30 minutes with either saline solution or one of the following pharmacologic agents, each tested at three different concentrations: group 1, saline solution (control, n = 14); groups 2 through 4, heparin (5000 units/ml, n = 8; 2500 units/ml, n = 6; and 1250 units/ml, n = 6, respectively); groups 5 through 7, urokinase (50,000 units/ml, n = 8; 25,000 units/ml, n = 6; and 12,500 units/ml, n = 6, respectively), and groups 8 through 10, ancrod (70 units/ml, n = 8; 35 units/ml, n = 6; and 17.5 units/ml, n = 6). Superoxide anion production was measured by the reduction of cytochrome c in a spectrophotometric assay. Chemotaxis was evaluated by the number of PMNs migrating across a filter with a Neuro Probe chamber (Neuro Probe, Cabin John, Md.). Phagocytosis was determined by the ingestion of opsonized zymosan particles by PMNs. Serum obtained from each PMN donor was used both to opsonize the zymosan and as a chemoattractant in the chemotaxis assay. Statistical comparison was evaluated by analysis of variance, and post hoc comparisons for each agent with control were performed with the unpaired Student t test. No agent, at any dose, significantly changed superoxide anion production compared with control cells. All three agents significantly inhibited PMN chemotaxis (p < 0.01). In the control group the number of PMNs counted was 27.6 ± 4.9. In groups 2 through 4 (heparin) the numbers were 15.2 ± 1.2, 18.3 ± 1.6, and 19.8 ± 2.8, respectively; in groups 5 through 7 (urokinase) they were 17.1 ± 2.0, 18.5 ± 2.7, and 22.2 ± 3.1, respectively; and in groups 8 through 10 (ancrod) they were 16.7 ± 3.1, 18.2 ± 3.2, and 20.3 ± 4.3, respectively. In the phagocytotic assay, heparin, urokinase, and ancrod reduced phagocytic activity in the high-dose (p < 0.01) and intermediate-dose groups (heparin, group 3, and urokinase, group 6, p < 0.01; ancrod, group 9, p < 0.05). However, in the low-dose groups only heparin produced a significant inhibition (p < 0.05). In the control group the percentage of PMNs that had ingested the opsonized zymosan was 19.8% ± 4.5%. In groups 2 through 4 (heparin) the numbers were 11.0 ± 1.9, 13.2 ± 2.6, and 16.0 ± 3.3, respectively; in groups 5 through 7 (urokinase) they were 12.2 ± 1.5, 14.5 ± 4.0, and 21.7 ± 6.9, respectively; and in groups 8 through 10 (ancrod) they were 13.0 ± 1.8, 15.5 ± 2.6, and 17.7 ± 5.7, respectively. We conclude that (1) heparin, urokinase, and ancrod inhibit PMN chemotaxis and phagocytosis in vitro and (2) superoxide anion production, which reflects PMN stimulation, was not affected by these agents in vitro. (J Vasc Surg 1992;16:565–74.)" @default.
- W4320804044 created "2023-02-15" @default.
- W4320804044 creator A5002793589 @default.
- W4320804044 creator A5029212911 @default.
- W4320804044 creator A5057817210 @default.
- W4320804044 creator A5081871306 @default.
- W4320804044 date "1992-10-01" @default.
- W4320804044 modified "2023-10-15" @default.
- W4320804044 title "Heparin, urokinase, and ancrod alter neutrophil function" @default.
- W4320804044 cites W1820892837 @default.
- W4320804044 cites W1988257363 @default.
- W4320804044 cites W2001045964 @default.
- W4320804044 cites W2008356007 @default.
- W4320804044 cites W2009373505 @default.
- W4320804044 cites W2011513090 @default.
- W4320804044 cites W2020704694 @default.
- W4320804044 cites W2026015458 @default.
- W4320804044 cites W2026123741 @default.
- W4320804044 cites W2026267319 @default.
- W4320804044 cites W2035607048 @default.
- W4320804044 cites W2038823462 @default.
- W4320804044 cites W2039573204 @default.
- W4320804044 cites W2076989520 @default.
- W4320804044 cites W2080711827 @default.
- W4320804044 cites W2082159691 @default.
- W4320804044 cites W2090522535 @default.
- W4320804044 cites W2096265656 @default.
- W4320804044 cites W2097744068 @default.
- W4320804044 cites W2109733205 @default.
- W4320804044 cites W2115917298 @default.
- W4320804044 cites W2131414371 @default.
- W4320804044 cites W2132405869 @default.
- W4320804044 cites W2151067784 @default.
- W4320804044 cites W2153852857 @default.
- W4320804044 cites W2157085619 @default.
- W4320804044 cites W2337937663 @default.
- W4320804044 cites W4320581066 @default.
- W4320804044 doi "https://doi.org/10.1016/0741-5214(92)90164-4" @default.
- W4320804044 hasPublicationYear "1992" @default.
- W4320804044 type Work @default.
- W4320804044 citedByCount "8" @default.
- W4320804044 countsByYear W43208040442013 @default.
- W4320804044 countsByYear W43208040442018 @default.
- W4320804044 countsByYear W43208040442019 @default.
- W4320804044 countsByYear W43208040442023 @default.
- W4320804044 crossrefType "journal-article" @default.
- W4320804044 hasAuthorship W4320804044A5002793589 @default.
- W4320804044 hasAuthorship W4320804044A5029212911 @default.
- W4320804044 hasAuthorship W4320804044A5057817210 @default.
- W4320804044 hasAuthorship W4320804044A5081871306 @default.
- W4320804044 hasBestOaLocation W43208040441 @default.
- W4320804044 hasConcept C126322002 @default.
- W4320804044 hasConcept C134018914 @default.
- W4320804044 hasConcept C160448771 @default.
- W4320804044 hasConcept C16685009 @default.
- W4320804044 hasConcept C170493617 @default.
- W4320804044 hasConcept C181199279 @default.
- W4320804044 hasConcept C185592680 @default.
- W4320804044 hasConcept C198677920 @default.
- W4320804044 hasConcept C202751555 @default.
- W4320804044 hasConcept C203014093 @default.
- W4320804044 hasConcept C2776892390 @default.
- W4320804044 hasConcept C2776914184 @default.
- W4320804044 hasConcept C2777397205 @default.
- W4320804044 hasConcept C2777557582 @default.
- W4320804044 hasConcept C2778870864 @default.
- W4320804044 hasConcept C2779866169 @default.
- W4320804044 hasConcept C2780795997 @default.
- W4320804044 hasConcept C2780868729 @default.
- W4320804044 hasConcept C54166955 @default.
- W4320804044 hasConcept C55493867 @default.
- W4320804044 hasConcept C71924100 @default.
- W4320804044 hasConcept C89372155 @default.
- W4320804044 hasConcept C98274493 @default.
- W4320804044 hasConceptScore W4320804044C126322002 @default.
- W4320804044 hasConceptScore W4320804044C134018914 @default.
- W4320804044 hasConceptScore W4320804044C160448771 @default.
- W4320804044 hasConceptScore W4320804044C16685009 @default.
- W4320804044 hasConceptScore W4320804044C170493617 @default.
- W4320804044 hasConceptScore W4320804044C181199279 @default.
- W4320804044 hasConceptScore W4320804044C185592680 @default.
- W4320804044 hasConceptScore W4320804044C198677920 @default.
- W4320804044 hasConceptScore W4320804044C202751555 @default.
- W4320804044 hasConceptScore W4320804044C203014093 @default.
- W4320804044 hasConceptScore W4320804044C2776892390 @default.
- W4320804044 hasConceptScore W4320804044C2776914184 @default.
- W4320804044 hasConceptScore W4320804044C2777397205 @default.
- W4320804044 hasConceptScore W4320804044C2777557582 @default.
- W4320804044 hasConceptScore W4320804044C2778870864 @default.
- W4320804044 hasConceptScore W4320804044C2779866169 @default.
- W4320804044 hasConceptScore W4320804044C2780795997 @default.
- W4320804044 hasConceptScore W4320804044C2780868729 @default.
- W4320804044 hasConceptScore W4320804044C54166955 @default.
- W4320804044 hasConceptScore W4320804044C55493867 @default.
- W4320804044 hasConceptScore W4320804044C71924100 @default.
- W4320804044 hasConceptScore W4320804044C89372155 @default.
- W4320804044 hasConceptScore W4320804044C98274493 @default.
- W4320804044 hasIssue "4" @default.